| 
				   | 
			
		| (3 intermediate revisions not shown.) | 
| Line 1: | 
Line 1: | 
|   | + |  | 
|   | ==Structure of an Anti-Methotrexate CDR1-3 Graft VHH Antibody in Complex with Methotrexate==  |   | ==Structure of an Anti-Methotrexate CDR1-3 Graft VHH Antibody in Complex with Methotrexate==  | 
| - | <StructureSection load='3qxt' size='340' side='right' caption='[[3qxt]], [[Resolution|resolution]] 1.70Å' scene=''>  | + | <StructureSection load='3qxt' size='340' side='right'caption='[[3qxt]], [[Resolution|resolution]] 1.70Å' scene=''>  | 
|   | == Structural highlights ==  |   | == Structural highlights ==  | 
| - | <table><tr><td colspan='2'>[[3qxt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QXT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QXT FirstGlance]. <br>  | + | <table><tr><td colspan='2'>[[3qxt]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QXT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QXT FirstGlance]. <br>  | 
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=MTX:METHOTREXATE'>MTX</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>  | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.7Å</td></tr>  | 
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1i3u|1i3u]], [[2x6m|2x6m]], [[3qxu|3qxu]], [[3qxv|3qxv]], [[3qxw|3qxw]]</td></tr>  | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=MTX:METHOTREXATE'>MTX</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>  | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qxt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qxt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3qxt RCSB], [http://www.ebi.ac.uk/pdbsum/3qxt PDBsum]</span></td></tr>  | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qxt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qxt OCA], [https://pdbe.org/3qxt PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qxt RCSB], [https://www.ebi.ac.uk/pdbsum/3qxt PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qxt ProSAT]</span></td></tr>  | 
|   | </table>  |   | </table>  | 
|   | <div style="background-color:#fffaf0;">  |   | <div style="background-color:#fffaf0;">  | 
| Line 15: | 
Line 16: | 
|   | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>  |   | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>  | 
|   | </div>  |   | </div>  | 
|   | + | <div class="pdbe-citations 3qxt" style="background-color:#fffaf0;"></div>  | 
|   | + |  | 
|   | + | ==See Also==  | 
|   | + | *[[Antibody 3D structures|Antibody 3D structures]]  | 
|   | + | *[[3D structures of non-human antibody|3D structures of non-human antibody]]  | 
|   | == References ==  |   | == References ==  | 
|   | <references/>  |   | <references/>  | 
| Line 20: | 
Line 26: | 
|   | </StructureSection>  |   | </StructureSection>  | 
|   | [[Category: Lama glama]]  |   | [[Category: Lama glama]]  | 
| - | [[Category: Fanning, S W]]  | + | [[Category: Large Structures]]  | 
| - | [[Category: Horn, J R]]  | + | [[Category: Fanning SW]]  | 
| - | [[Category: Anti-hapten antibody]]  | + | [[Category: Horn JR]]  | 
| - | [[Category: Antibody]]
  | + |  | 
| - | [[Category: Camelid single domain antibody]]
  | + |  | 
| - | [[Category: Cdr]]
  | + |  | 
| - | [[Category: Hapten binding]]
  | + |  | 
| - | [[Category: Heavy chain only]]
  | + |  | 
| - | [[Category: Immune system]]
  | + |  | 
| - | [[Category: Ligand binding]]
  | + |  | 
| - | [[Category: Low molecular weight compound]]
  | + |  | 
| - | [[Category: Methotrexate]]
  | + |  | 
| - | [[Category: Small molecule sensing]]
  | + |  | 
| - | [[Category: Vhh]]
  | + |  | 
 |   Structural highlights 
  Publication Abstract from PubMed 
Conventional anti-hapten antibodies typically bind low-molecular weight compounds (haptens) in the crevice between the variable heavy and light chains. Conversely, heavy chain-only camelid antibodies, which lack a light chain, must rely entirely on a single variable domain to recognize haptens. While several anti-hapten VHHs have been generated, little is known regarding the underlying structural and thermodynamic basis for hapten recognition. Here, an anti-methotrexate VHH (anti-MTX VHH) was generated using grafting methods whereby the three complementarity determining regions (CDRs) were inserted onto an existing VHH framework. Thermodynamic analysis of the anti-MTX VHH CDR1-3 Graft revealed a micromolar binding affinity, while the crystal structure of the complex revealed a somewhat surprising noncanonical binding site which involved MTX tunneling under the CDR1 loop. Due to the close proximity of MTX to CDR4, a nonhypervariable loop, the CDR4 loop sequence was subsequently introduced into the CDR1-3 graft, which resulted in a dramatic 1000-fold increase in the binding affinity. Crystal structure analysis of both the free and complex anti-MTX CDR1-4 graft revealed CDR4 plays a significant role in both intermolecular contacts and binding site conformation that appear to contribute toward high affinity binding. Additionally, the anti-MTX VHH possessed relatively high specificity for MTX over closely related compounds aminopterin and folate, demonstrating that VHH domains are capable of binding low-molecular weight ligands with high affinity and specificity, despite their reduced interface.
 An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop.,Fanning SW, Horn JR Protein Sci. 2011 Jul;20(7):1196-207. doi: 10.1002/pro.648. Epub 2011 May, 23. PMID:21557375[1]
 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. 
 
 
 See Also
  References 
- ↑ Fanning SW, Horn JR. An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop. Protein Sci. 2011 Jul;20(7):1196-207. doi: 10.1002/pro.648. Epub 2011 May, 23. PMID:21557375 doi:10.1002/pro.648
  
 
  |